China Immunotech closes RMB45m Series A led byCCB Principal Capital

In January 2020, China Immunotech successfully completed its Series A financing round of 45 million yuan led by CCB Principal Capital, and joined by Grower Venture Capital and Zhejiang Huacheng Holdings Group. Earlier, the company received tens of millions of yuan in early investment from Lotus Lake Ventures and QF Ventures.

In January 2020, China Immunotech successfully completed its Series A financing round of 45 million yuan led by CCB Principal Capital, and joined by Grower Venture Capital and Zhejiang Huacheng Holdings Group.Earlier, the company received tens of millions of yuan in early investment from Lotus Lake Ventures and QF Ventures.

China Immunotech was established in March 2018 by Professor Lin Xin, a prominent immunologist who has been involved in immunological research related to T cell activation for more than 20 years. The company focuses on the development and commercialization of cellular immunotherapy products for various diseases represented by TCR-T.

Within two years of the inception of China Immunotech, a product development team of more than 40 members has been established, and attracted several professionals with rich experience in drug development. The core technical staff are immunology or medical doctors who have graduated from prominentuniversities.

The company has obtained equity financing and government project funding totaling nearly 100 million yuan. It has applied for six new technology innovation patents, and carried out in-depth cooperation with the Cancer Immunology Laboratory of Tsinghua University.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/07/china-immunotech-closes-rmb45m-series-a-led-byccb-principal-capital/.

Leave a Reply

Please Login to Comment